

# STN SEARCH TRANSCRIPT 10/502,255

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspal623zct

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEMS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEMS 2 "Ask CAS" for self-help around the clock  
NEMS 3 New STN Analyst pricing effective March 1, 2006  
NEMS 4 STN Analyst \$500 visualization usage credit offered  
NEMS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records  
NEMS 6 MAY 11 KOREAPAT updates resume  
NEMS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEMS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and  
USPATFILL/USPAT2  
NEMS 9 MAY 30 The F-term thesaurus is now available in CA/CAPLUS  
NEMS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEMS 11 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEMS 12 JUN 28 Price changes in full-text patent databases EFPULL and PCFPULL  
NEMS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEMS 14 JUL 14 ESTA enhanced with Japanese patents  
NEMS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEMS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEMS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0c(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEMS HOURS STN Operating Hours Plus Help Desk Availability  
NEMS LOGIN Welcome Banner and News Items  
NEMS IPC8 For general information regarding STN implementation of IPC 8  
NEMS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:16:32 ON 24 AUG 2006

=> FILE REG COST IN U.S. DOLLARS SINCE FILE ENTRY SESSION TOTAL  
FULL ESTIMATED COST 0.42 0.42  
FILE 'REGISTRY' ENTERED AT 13:17:28 ON 24 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/YINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4  
DICTIONARY FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH JUNE 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\SUBSTANCE P PIPERIDINES.str



chain nodes :  
25 30 31 32  
ring nodes :  
1 2 3 4 5 6 9 10 11 12 13 14 16 17 18 19 20 21 22 23 24 33 34  
35 36 37 38  
chain bonds :

1-9 6-30 22-25 30-31 31-32 32-33  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 16-17 16-21  
17-18 18-19 19-20 19-22 20-21 20-24 22-23 23-24 33-34 33-38 34-35 35-36  
36-37 37-38  
exact/normal bonds :  
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-30 16-17 16-21 17-18 18-19 19-20 19-22  
20-21 20-24 22-23 22-25 23-24 30-31 31-32 32-33  
normalized bonds :  
9-10 9-14 10-11 11-12 12-13 13-14 33-34 33-38 34-35 35-36 36-37 37-38  
isolated ring systems :  
containing 1 : 9 : 16 : 33 :

G1:C,N  
G2:C,O,N  
G3:C,S

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom  
23:Atom 24:Atom 25:CLASS 29:Atom 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom  
35:Atom 36:Atom 37:Atom 38:Atom

L1 STRUCTURE UPLOADED

=> D L1  
L1 HAS NO ANSWERS  
STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*  
Structure attributes must be viewed using STN Express query preparation.

=> S L1  
SAMPLE SEARCH INITIATED 13:17:59 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 564 TO ITERATE

100.08 PROCESSED 564 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00:00:01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: BATCH 9856 TO 12704  
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> S L1 SSS FULL  
FULL SEARCH INITIATED 13:18:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 11966 TO ITERATE

100.08 PROCESSED 11966 ITERATIONS 43 ANSWERS  
SEARCH TIME: 00:00:01

L3 43 SEA SSS FULL L1

=> FILE CAPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION  
166.94 167.36

FILE 'CAPLUS' ENTERED AT 13:18:08 ON 24 AUG 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9  
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)  
Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3  
L4 3 L3  
=> D 1-3 IBIB ABS HITSTR

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER:  
DOCUMENT NUMBER:  
TITLE:

Combinations of paroxetine and 2-(R)-(4-fluoro-2-methylphenyl)-4-(S)-((8a)-6-oxohexahydro-1,2-pyrazin-2-yl)piperidine-1-carboxylic acid  
[1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethyl]methylamide  
for treatment of depression/anxiety  
Molotto, Sergio; Corsi, Mauro; Carletti, Renzo  
Glaxo Group Limited, UK  
PCT Int. Appl., 25 pp.  
CODEN: PIKAD2

INVENTOR(S):  
PATENT ASSIGNEE(S):  
SOURCE:  
DOCUMENT TYPE:  
LANGUAGE:  
FAMILY ACC. NUM. COUNT:  
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2004091615 A1 20041028 WO 2004-EP4121 20040416  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, HT, IL, IN, LU, NI, NL, SE, MC, PT, TD, TG  
EP 1615641 A1 20060118 EP 2004-739085 20040416  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NI, NL, SE, MC, PT,

RELATED CASE  
(NO U.S.)

IE, SI, IT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
PRIORITY APPL. INFO.:

AB 2003-8968 A 20030417  
GB 2004-EP4121 W 20040416  
MO 2004-EP4121


AB The present invention relates to therapeutic combinations comprising  
paroxetine or salts or solvates thereof and 2-(R)-(4-fluoro-2-  
methylphenyl)-4-(S)-((8aS)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2-  
yl)piperidine-1-carboxylic acid [1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethyl]  
methylamide (I) or salts or solvates thereof, and to pharmaceutical  
compos. containing the combinations and their use in the treatment of  
depression and/or anxiety. Thus, tablets contained paroxetine-HCl  
hemihydrate 7.5, I-HCl 1, dibasic calcium phosphate 106.75, Mg stearate  
1.5, Crospovidone 4.5, and colloidal silica 0.75 mg.  
IT 579475-18-6 579475-21-1 781647-19-6  
781647-20-9

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USBS (Uses)

(combinations of paroxetine and (oxohexahydropyrrolopyrazinyl)piperidin  
ecarboxylic acid (bistrifluoromethylphenyl)ethylmethylamide for  
treatment of depression/anxiety)


RN 579475-18-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-21-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

● HCl




RN 781647-19-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-  
2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-  
2(1H)-yl]-N-methyl-, (2R,4S)-, mixt. with (3S,4R)-3-[(1,3-benzodioxol-5-  
yloxy)methyl]-4-(4-fluorophenyl)piperidine (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
CMF C31 H35 F7 N4 O2

Absolute stereochemistry.



CM 2

CRN 61869-08-7  
CMF C19 H20 F N O3

Absolute stereochemistry. Rotation (-).




designed to elicit measurements relating to efficacy and safety across a range of three doses. The primary endpoint was adequate relief of FD pain or discomfort, secondary endpoint included (1) changes in daily upper abdominal pain severity ratings, (2) proportion of pain free days, (3) changes in self-ratings of nausea, early satiety, bloating or distension, postprandial fullness and burping or belching, and (4) changes in quality of life.

IT 579475-18-6 579475-21-1 579475-24-4  
733041-57-1

RL: THU (Therapeutic use); BIOI (Biological study); USES (Uses)  
(NK1 receptor antagonists for treatment of functional dyspepsia)


RN 579475-18-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-21-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-24-4 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
CMF C31 H35 F7 N4 O2


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 733041-57-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 579475-18-6  
CMF C31 H35 F7 N4 O2

Absolute stereochemistry.



CM 2  
CRN 75-75-2  
CMF C H4 O3 S




14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2003:633712 CAPLUS  
DOCUMENT NUMBER: 139:180087  
TITLE: Preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists.  
INVENTOR(S): Alvaro, Giuseppe; Di Fabio, Romano; Tranquillini, Maria Elvira; Spada, Simone  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 65 pp.  
CODEN: PIKX22  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066635	AI	20030814	WO 2003-EP1308	20030210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KI, KM, KN, KR, KZ, LC, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, PU, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SV, SW, SY, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	AI	20030814	CA 2003-2475619	20030210
CA 2475619	AI	20030902	AU 2003-205753	20030210
AU 200305753	AI	20041103	EP 2003-102621	20030210
EP 1472256	AI	20041103		


APPLICANTS

EP 1472256	B1	20051102	GB, GR, IT, LI, LU, NL, SE, SK, PT, DE, DK, ES, FR, RO, MK, CY, AT, TR, BG, CZ, EE, HU, SR, IE, SI, LT, LV, FI, 20041207
BR 2003007123	A	20050615	BR 2003-2123
CN 1628115	A	20050811	CN 2003-803431
US 2005176715	A1	20050811	US 2003-502255
JP 2005524637	T2	20050818	JP 2003-556498
AT 308543	E	20051115	AT 2003-702621
ES 2250870	T3	20060416	ES 2003-3702621
EP 1666465	A1	20060607	EP 2005-77500
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, AL, TR, BG, CZ, EE, HU, SK, ZA 2004004842	A	20050726	ZA 2004-4842
NO 2004003239	A	20040802	NO 2004-3239
PRIORITY APPLN. INFO.:			GB 2002-3020
			EP 2003-702621
			WO 2003-EP1308
OTHER SOURCE(S):			W 20030210
GI			



AB Title compds. [I; R = halo, Cl-4 alkyl; R1 = Cl-4 alkyl; R2, R3 = H, Cl-4 alkyl; R4 = CF3, Cl-4 alkyl, Cl-4 alkoxy, OCF3, halo; R5 = H, Cl-4 alkyl, C3-7 cycloalkyl; R6 = H, R7 = OH, or vice versa; X = CH2, NR5, O; Y = N, Z = CH, or vice versa; A = CO, SOq; when Y = N and Z = CH, A = SOq; m = 0-3; n = 1-3; p, q = 1, 2], were prepared. Thus, 2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [3,5-bis(trifluoromethyl)benzyl]methanamide (preparation given) and hexahydroindolizino[1,2-a]pyrazin-6-one (preparation given) were stirred 15 min. in MeCN; NaBH(OAc)3 was added and the mixture was stirred 2 days to give 2-(R)-(4-fluoro-2-methylphenyl)-4-(R)-(6-oxohexahydroindolizino[1,2-a]pyrazin-2-yl)piperidine-1-carboxylic acid [3,5-bis(trifluoromethyl)benzyl]methanamide and 2-(R)-(4-fluoro-2-methylphenyl)-4-(S)-(6-oxohexahydroindolizino[1,2-a]pyrazin-2-yl)piperidine-1-carboxylic acid [3,5-bis(trifluoromethyl)benzyl]methanamide. I showed NK1 receptor binding activity with pKi = 9.4-11.0. I pharmaceutical compns. are claimed.

IT 579475-21-IP 579475-23-3P  
579475-21-IP 579475-23-3P  
RL: PKC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THO (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists)  
RN 579475-21-1 CAPLUS  
CN 1-piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)-(9CI) (CA INDEX NAME)  
Absolute stereochemistry.




● HCl

RN 579475-23-3 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, dihydrate, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

● 2 H2O

PAGE 2-A


IT 579474-94-5P 579474-97-8P 579474-99-0P

579475-01-7P 579475-03-9P 579475-05-1P  
579475-07-3P 579475-09-5P 579475-11-9P  
579475-13-1P 579475-15-3P 579475-17-5P  
579475-18-6P 579475-20-0P 579475-24-4P  
579475-26-6P 579475-28-8P 579475-30-2P  
579475-31-3P 579475-33-5P 579475-35-7P  
579475-37-9P 579475-39-1P 579475-41-5P  
579475-43-7P 579475-45-9P 579475-48-2P  
579475-50-6P 579475-52-8P 579475-54-0P  
579475-56-2P 579475-57-3P 579475-59-5P  
579475-61-9P 579475-63-1P 579475-65-3P  
579475-13-4P 579475-16-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolopyrazinylpiperidinecarboxamides as tachykinin antagonists)


RN 579474-94-5 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579474-97-8 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579474-99-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




RN 579475-01-7 CAPLUS  
CN 1-Piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


● HCl

PAGE 2-A



RN 579475-03-9 CAPLUS  
CN 1-Piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-05-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-N-methyl-, monohydrochloride, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 579475-07-3 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-09-5 CAPLUS


CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-11-9 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-13-1 CAPLUS  
 CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 579475-15-3 CAPLUS  
CN 1-piperidinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 579475-17-5 CAPLUS


CN 1-piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-18-6 CAPLUS  
CN 1-piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-20-0 CAPLUS  
CN 1-piperidinecarboxamide, N-([1R]-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluoro-2-methylphenyl)-4-[(8a)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 579475-24-4 CAPIUS  
 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 579475-18-6  
 CMF C31 H35 F7 N4 O2


Absolute stereochemistry.



CM 2


CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 579475-26-6 CAPIUS  
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-28-8 CAPIUS  
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579475-30-2 CAPIUS  
 CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 579475-31-3 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 579475-33-5 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-35-7 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 579475-37-9 CAPIUS  
CN 1-Piperidinecarboxamide, N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PN	579475-39-1	CARBUS
CN	1-Piperidinoecarboxamide, N-(1 <i>S</i> )-1-[3,5-bis(trifluoromethyl)phenyl]ethyl)-2-(4-fluorodimethylphenyl)-4-(6 <i>bar</i> -hexahydro-6-oxopyrrolo[1,2- <i>a</i> ]pyrazin-2(1 <i>H</i> )-yl)-N-methyl-, (2 <i>R</i> ,4 <i>S</i> )-(9 <i>CI</i> )	(CA INDEX NAME)

**Absolute stereochemistry.**




RN	CAPLUS
579475-41-5	1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8 <i>S</i> )-6-oxo-6-oxopropylol-1,2- <i>a</i> ]pyrazin-2(1 <i>H</i> )-yl]-N-methyl-, (2 <i>R</i> ,4 <i>R</i> )-(9 <i>CI</i> ) (CA INDEX NAME)

**Absolute stereochemistry.**



RN 579475-43-7 CAPLUS  
 1-piperidinecarboxamide, N-((3,5-dichlorophenyl)methyl)-2-(4-fluoro-2-methylphenyl)-4-(18s)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4S)-(9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



NR	CAPLUS
579475-45-9	1-Piperidinecarboxamide, N-[(1,3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)-(9CI) (CA INDEX NAME)

### Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A

RN 579475-48-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aS)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A


RN 579475-50-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

methyl-, (2R,4R)- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.



RN 579475-52-8 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 579475-54-0 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 2-A

RN 579475-56-2 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-(4-fluoro-2-methylphenyl)-4-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)  
Absolute stereochemistry.

PAGE 1-A




● HCl


PAGE 2-A

RN 579475-57-3 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-


yl]-N-methyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.



RN 579475-59-5 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2S,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.



RN 579475-61-9 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2S,5S)-rel- (9CI) (CA INDEX NAME)  
Relative stereochemistry.




● HCl

RN 579475-63-1 CAPLUS


CN 579476-13-4 CAPLUS  
2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (2R,5R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 579475-65-3 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, monohydrochloride, (2R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

RN 579476-13-4 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-bis(trifluoromethyl)phenyl)ethyl]-2-(4-fluoro-2-methylphenyl)-4-(hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 579476-16-7 CAPLUS  
CN 2-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1-(4-fluoro-2-methylphenyl)-5-[(8aR)-hexahydro-6-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-methyl-, (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> LOG HOLD  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
CA SUBSCRIBER PRICE  
SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 13:18:33 ON 24 AUG 2006

SINCE FILE	TOTAL
ENTRY	15.79
ENTRY	-2.25
ENTRY	-2.25